Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada (NASDAQ: KMDA) provided 2026 annual guidance of $200–$205 million in revenues and $50–$53 million of adjusted EBITDA, representing a midpoint increase of 13% revenue and 23% adjusted EBITDA versus the midpoint of its 2025 guidance. The company affirmed 2025 guidance of $178–$182 million in revenues and $40–$44 million of adjusted EBITDA and expects ~$75 million of year-end cash for 2025. 2026 guidance is based solely on continued organic growth across Proprietary and Distribution segments, with growth drivers cited as U.S. sales expansion, higher ex-U.S. sales of KAMRAB, GLASSIA, HEPAGAM and VARIZIG, Distribution launches in Israel and MENA, and increased plasma collection in Texas.
Kamada (NASDAQ: KMDA) was awarded a two-year extension by Canadian Blood Services to supply four specialty plasma-derived products (WINRHO, HEPAGAM, CYTOGAM, VARIZIG) from Q2-2026 to Q1-2028. The award is valued at $10–$14 million, securing approximately $5.0–$7.0 million of annual sales during that period. All four products are approved by Health Canada and the FDA. Kamada reiterated its 2025 revenue guidance of $178–$182 million and adjusted EBITDA guidance of $40–$44 million, and projected double-digit revenue and profitability growth for 2026 with detailed guidance due in January 2026.
Kamada (NASDAQ: KMDA) announced it will discontinue its Phase 3 InnovAATe trial of inhaled AAT after a prespecified interim futility analysis found the study is unlikely to meet its primary endpoint of lung function (FEV1).
The company said the decision is efficacy‑related and not due to safety concerns, and it will continue supplying GLASSIA (AAT-IV) internationally, including the U.S. and Canada via its licensee TAKEDA. Kamada reiterated its 2025 revenue guidance of $178M–$182M and adjusted EBITDA guidance of $40M–$44M, and projected double-digit revenue and profitability growth in 2026, with detailed guidance to follow in January 2026. Management will host a conference call today at 8:30am ET.
Kamada (NASDAQ: KMDA) reported strong Q3 and nine-month 2025 results, with Q3 revenue $47.0M (+13% YoY) and Q3 adjusted EBITDA $11.7M (+34% YoY). Nine-month revenue was $135.8M (+11% YoY) with adjusted EBITDA of $34.2M (+35% YoY). The company generated $17.9M cash from operations in the first nine months and held $72.0M cash as of Sep 30, 2025. Kamada reiterated full-year 2025 guidance of $178M–$182M revenue and $40M–$44M adjusted EBITDA. Key operational updates: FDA approval for Houston plasma center, launch of the SHIELD CYTOGAM investigator study, and an interim futility analysis for the InnovAATe Phase 3 trial due this quarter.
Kamada (NASDAQ: KMDA) announced on November 4, 2025 that the first patient was enrolled in an investigator-initiated, post-marketing randomized controlled multicenter trial named SHIELD testing CYTOGAM (Cytomegalovirus Immune Globulin Intravenous) to prevent late CMV disease in high-risk kidney transplant recipients (donor CMV seropositive / recipient seronegative).
The study will evaluate CYTOGAM dosed at the end of standard antiviral prophylaxis to reduce clinically significant late CMV; it is led by Camille Kotton, M.D., and David Wojciechowski, D.O. The release notes that up to one third of kidney transplant patients may develop late CMV after stopping prophylaxis.
Kamada (NASDAQ: KMDA) will release its third quarter and nine months ended September 30, 2025 financial results on Monday, November 10, 2025 before U.S. market open. Management will host an investor conference call on November 10, 2025 at 8:30 AM Eastern Time to discuss results and answer questions.
Shareholders can join by phone using conference ID 13756537 (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) or listen via live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
Kamada (NASDAQ: KMDA) announced that Amir London, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 9:20 a.m. ET at the Lotte New York Palace Hotel in New York.
Mr. London will also be available for one-on-one investor meetings throughout the conference; investors should arrange meetings through their Stifel representative. A live webcast of the presentation will be available via the company-provided link.
Kamada (NASDAQ: KMDA), a global biopharmaceutical company specializing in rare conditions and specialty plasma-derived products, announced its participation in two major investor conferences in September 2025.
CEO Amir London will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 PM ET, and the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:00 AM ET. One-on-one investor meetings will be available at both conferences, with live webcasts accessible through provided links.
Kamada (NASDAQ: KMDA) reported strong financial results for Q2 and H1 2025, with significant growth in both revenue and profitability. First half 2025 revenues reached $88.8 million, up 11% year-over-year, while Q2 revenues were $44.8 million, a 5% increase. The company's adjusted EBITDA for H1 2025 grew 35% to $22.5 million, representing a 25% margin.
Based on robust performance, Kamada raised its 2025 adjusted EBITDA guidance to $40-44 million and maintained revenue guidance of $178-182 million. The company received FDA approval for its Houston plasma collection center, with an estimated annual revenue potential of $8-10 million at full capacity. Additionally, Kamada continues to advance its Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy.
Kamada Ltd. (NASDAQ: KMDA) has received FDA approval for its plasma collection center in Houston, Texas, allowing commercial sales of normal source plasma. The 12,000 square foot facility features 50 donor beds with an annual collection capacity of 50,000 liters of plasma.
The Houston center, positioned to be one of the largest specialty plasma collection sites in the U.S., is expected to generate $8-10 million in annual revenue at full capacity. The facility will collect both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D. This marks Kamada's third Texas-based site, alongside locations in San Antonio and Beaumont.